Zoryl-MF 2 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 2 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The prolonged-release formulation of Zoryl-MF 2 ensures a sustained therapeutic effect, promoting better glycemic stability and patient compliance. This combination is particularly beneficial for patients inadequately controlled by diet and exercise alone or those requiring dual therapy to achieve target blood glucose levels. Zoryl-MF 2 should be used as part of a comprehensive diabetes management plan, including diet modification, physical activity, and regular monitoring of blood glucose. Contraindications include severe renal impairment, metabolic acidosis, and known hypersensitivity to either component. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and lactic acidosis in rare cases. Dose adjustment and careful monitoring are advised in patients with renal or hepatic impairment. Zoryl-MF 2 Tablet PR offers an effective and convenient option for optimizing glycemic control in type 2 diabetes patients.